We found significantly differential KCC2 expression in pan-cancers, such as breast invasive carcinoma, liver hepatocellular carcinoma, glioma, prostate adenocarcinoma, and uterine carcinosarcoma. This evidence concerns the gene SLC12A5 and prostate adenocarcinoma.